ノースカロライナにおける子宮内膜がんの臨床試験
ノースカロライナ内の拠点で、子宮内膜がんに関する31件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
Tirzepatide in Obesity-Driven Endometrial Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
被験者募集中早期第1相
18歳以上 · 女性 · 2026/10/02更新 · NCT07065552Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- Southeastern Medical Oncology Center-Clinton, Clinton
- 他8件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
被験者募集中
18歳以上 · 全性別 · 2026/10/02更新 · NCT07059884A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Carolina Cancer Research Center, Wilson
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Southeastern Medical Oncology Center-Clinton, Clinton
- Duke University Medical Center, Durham
- 他3件
被験者募集中第3相
18歳以上 · 女性 · 2026/10/02更新 · NCT07198074Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Duke University Medical Center, Durham
- Duke Women's Cancer Care Raleigh, Raleigh
被験者募集中第2相
18歳以上 · 女性 · 2026/09/28更新 · NCT05112601DESTINY-PANTUMOUR04
- Research Site, Durham
- Research Site, Wilson
被験者募集中観察研究
18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
- Duke Womens Cancer Care Raleigh, Raleigh
被験者募集中第2相
18歳以上 · 女性 · 2026/09/24更新 · NCT05640999A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Duke Cancer Institute ( Site 6049), Durham
- FirstHealth of the Carolinas ( Site 6037), Pinehurst
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT06952504ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UNC- Chapel Hill, Chapel Hill
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Charlotte
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT05123482Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Atrium Health LCI - Morehead, Charlotte
- Atrium Health LCI - Ballantyne, Charlotte
- Atrium Health LCI - Concord, Concord
- 他3件
被験者募集中第3相
18歳以上 · 女性 · 2026/09/09更新 · NCT07166094A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Duke Cancer Institute, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06515613DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Charlotte
- Research Site, Charlotte
- Research Site, Winston-Salem
- 他1件
被験者募集中第3相
18歳以上 · 女性 · 2026/09/03更新 · NCT06989112A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Atrium Health - Wake Forest, Charlotte
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07470853FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Duke University, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264A Study of PHST001 in Advanced Solid Tumors
- Duke Cancer Institute, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT06840886A Study of DM002 in Patients With Advanced Solid Tumors
- Carolina BioOncology Institute, LLC, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/07更新 · NCT06751329Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Greenville
- Research Site, Pinehurst
被験者募集中第3相
18歳以上 · 女性 · 2026/07/29更新 · NCT07044336Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
- FirstHealth of the Carolinas, Inc., Pinehurst
被験者募集中第3相
18歳以上 · 女性 · 2026/07/28更新 · NCT07022483Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #131, Raleigh
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/23更新 · NCT06974110The Better, Harder, Faster, Stronger Study
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
被験者募集中観察研究
55歳以上 · 女性 · 2026/07/15更新 · NCT07220512Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Carolina BioOncology Institute, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/23更新 · NCT06993844ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
被験者募集中第1相
18歳以上 · 女性 · 2026/01/29更新 · NCT05542407A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Huntersville
被験者募集中第1相
18歳以上 · 全性別 · 2026/01/07更新 · NCT06999187Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Levine Cancer Institute, Charlotte
被験者募集中第2相
18歳以上 · 全性別 · 2025/11/13更新 · NCT05997017Multimedia Aid for Genetic Testing in Gynecologic Oncology
- Univeristy of North Carolina at Chapel Hill, Chapel Hill
被験者募集中
18歳以上 · 女性 · 2025/11/12更新 · NCT07084168SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- FirstHealth Carolinas, Pinehurst
被験者募集中第2/3相
18歳以上 · 女性 · 2024/05/02更新 · NCT05797831ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。